文献速递脊柱关节炎

难治性中轴型脊柱关节炎的10年发生率、基线相关因素与疾病负担:DESIR队列分析

Incidence, baseline-associated factors and burden of difficult-to-manage axial spondyloarthritis: a 10-year analysis of the DESIR cohort.
PubMed 文献 · RMD Open · 2026-09-07

基于法国DESIR前瞻性起始队列,纳入177例符合ASAS 2009标准且暴露于≥1种bDMARD的axSpA患者,评估难治性axSpA(D2M-axSpA)与治疗难治性axSpA(TR-axSpA)的累积发生率、基线相关因素及长期结局。按ASAS定义和扩展定义,D2M-axSpA累积发生率分别为6.8%和14.4%,TR-axSpA罕见;女性及基线疾病活动度较高与D2M-axSpA(扩展定义)相关,且该组纤维肌痛、医疗资源使用及阿片类药物使用更高。

要点

  • D2M-axSpA按ASAS定义累积发生率6.8%,扩展定义14.4%,TR-axSpA罕见。
  • 女性及基线较高疾病活动度与扩展定义D2M-axSpA发生相关。
  • 扩展定义D2M-axSpA者纤维肌痛、医疗访视及阿片使用更高。

核心结论

  • 在近期起病的axSpA起始队列长期随访中,D2M-axSpA少见,且罕与真正治疗难治或结构进展相关,但伴随持续疾病负担和显著社会经济影响。

研究设计与样本

  • 法国前瞻性DESIR队列研究,纳入177例符合ASAS 2009标准且暴露于≥1种bDMARD的axSpA患者,随访长达10年。

主要发现

  • D2M-axSpA累积发生率按ASAS定义为6.8%(95%CI 2.4 to 11.0),按扩展定义为14.4%(95%CI 8.3 to 20.2)。
  • TR-axSpA按ASAS定义和扩展定义的累积发生率分别为0.7%和3.7%。
  • 女性及基线较高疾病活动度与扩展定义D2M-axSpA发生相关。
  • 扩展定义D2M-axSpA患者纤维肌痛患病率60% vs 22.9%,累计医疗访视次数110 vs 60,阿片类药物使用100% vs 72%。

关键数值与推荐

  • D2M-axSpA和TR-axSpA按ASAS定义及扩展定义(≥3种b/靶向合成DMARDs失败,不论作用机制)分类。

临床怎么用

  • 对近期起病axSpA患者,应关注女性及基线高疾病活动度者的D2M-axSpA风险,并重视纤维肌痛、医疗资源使用及阿片类药物使用等患者中心结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine the cumulative incidence of difficult-to-manage axial spondyloarthritis (D2M-axSpA) and treatment-refractory axSpA (TR-axSpA) in a recent-onset axSpA inception cohort, identify baseline factors and characterise long-term outcomes. METHODS: Patients from the French prospective DESIR (DEvenir des Spondyloarthrites Indifférenciées Récentes) cohort fulfilling the Assessment of Spondyloarthritis International Society (ASAS) 2009 criteria for axSpA and exposed to ≥1 biologic disease-modifying antirheumatic drug (bDMARD) were included. Patients with D2M-axSpA and TR-axSpA were classified according to both the ASAS definition and an extended definition adapted to historical treatment availability (failure of ≥3 b/targeted synthetic DMARDs regardless of mechanism of action). Cox proportional hazards models were used to identify baseline factors associated with D2M-axSpA. Clinical, imaging and socio-economic outcomes were analysed over up to 10 years of follow-up. RESULTS: Among 177 patients exposed to ≥1 bDMARD, the cumulative incidence of D2M-axSpA was 6.8% (95% CI 2.4 to 11.0) and 14.4% (95% CI 8.3 to 20.2) using the ASAS and extended definitions, respectively, while TR-axSpA remained rare (0.7% and 3.7%, respectively). Female sex and higher baseline disease activity were associated with the development of D2M-axSpA (extended definition). During follow-up, patients with D2M-axSpA according to the extended definition had a higher prevalence of fibromyalgia (60% vs 22.9%), greater healthcare resource utilisation (cumulative number of medical visits 110 vs 60) and opioid use (100% vs 72%). CONCLUSION: In this recent-onset axSpA inception cohort with long-term follow-up, D2M-axSpA was rare, rarely associated with true treatment refractoriness or structural progression and was accompanied by a persistent disease burden carrying a substantial socio-economic impact, highlighting the need for a broader, patient-centred approach to its management. TRIAL REGISTRATION NUMBER: NCT01648907.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Fakih O, Moltó A, Verhoeven F, et al. Incidence, baseline-associated factors and burden of difficult-to-manage axial spondyloarthritis: a 10-year analysis of the DESIR cohort. RMD Open. 2026. PMID: 42705859. doi:10.1136/rmdopen-2026-007094

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。